10-Q: Denali Q3 2025: DNL310 BLA Review Extended, ALS Trial Fails

Denali Therapeutics reports Q3 2025 financial results with increased net losses, DNL310 BLA review extension, and discontinuation of the DNL343 ALS trial.

Summary

• Net loss for the three months ended September 30, 2025, was $126.9 million, an increase from $107.2 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $384.0 million, up from $308.0 million for the same period in 2024.
• Research and development expenses increased by $3.7 million (4%) for Q3 2025 and $24.2 million (8%) for the nine months ended September 30, 2025, driven by increased TV program spend and Salt Lake City facility operations, partially offset by winding down small molecule programs.
• General and administrative expenses rose by $10.6 million (42%) for Q3 2025 and $21.7 million (29%) for the nine months ended September 30, 2025, primarily due to preparations for a potential commercial launch of tividenofusp alfa (DNL310).
• Cash, cash equivalents, and marketable securities totaled $872.9 million as of September 30, 2025.
• The FDA extended the Prescription Drug User Fee Act (PDUFA) target action date for tividenofusp alfa (DNL310) Biologics License Application (BLA) from January 5, 2026, to April 5, 2026, to allow for submission of updated clinical pharmacology information.
• The Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 in the treatment of ALS did not meet its primary endpoint, and the active treatment extension was discontinued.
• Sanofi terminated its license to the central nervous system (CNS) Products program, including SAR443820/DNL788, in February 2025.
• Takeda terminated the ATV:TREM2 collaboration program on February 26, 2025, effective April 2025.
• The company officially opened its clinical biomanufacturing facility in Salt Lake City, Utah, in March 2025.
• FDA granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of individuals with MPS II in January 2025.
• FDA accepted the BLA for tividenofusp alfa for priority review in July 2025.
• Alignment was reached with the FDA that cerebrospinal fluid heparan sulfate (CSF HS) may be considered a reasonably likely surrogate endpoint to predict clinical benefit for DNL126 in MPS IIIA.
• Enrollment was completed in the ongoing Phase 1/2 study of DNL126 for MPS IIIA, and a global Phase 3 confirmatory study is being planned.
• A Clinical Trial Application (CTA) for DNL628 (OTV:MAPT) to initiate clinical studies in Alzheimer's disease was submitted in October 2025.
• An Investigational New Drug (IND) application for DNL952 (ETV:GAA) to begin clinical studies in Pompe disease was submitted in October 2025.

Sentiment

Score: 4

Explanation: While there are significant positive developments in key pipeline programs (DNL310, DNL126) and strategic operational improvements (new manufacturing facility), these are overshadowed by increased net losses, the failure of the DNL343 ALS trial, and the termination of two collaboration programs. The BLA review extension for DNL310, while for administrative reasons, adds uncertainty to a critical near-term approval. The overall financial position remains strong for the short term, but the increased burn rate and need for future capital raise temper enthusiasm.

Positives

• FDA granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for MPS II in January 2025, recognizing its potential to address an unmet medical need.
• The Biologics License Application (BLA) for tividenofusp alfa was accepted by the FDA for priority review in July 2025, indicating a faster review timeline for this key product candidate.
• The company opened its clinical biomanufacturing facility in Salt Lake City, Utah, in March 2025, enhancing manufacturing capabilities and supply chain control.
• Reached alignment with the FDA that cerebrospinal fluid heparan sulfate (CSF HS) may be a reasonably likely surrogate endpoint for accelerated approval of DNL126 in MPS IIIA, potentially expediting its development.
• Enrollment was completed in the Phase 1/2 study of DNL126 for MPS IIIA, with a global Phase 3 confirmatory study now being planned.
• Submitted a Clinical Trial Application (CTA) for DNL628 (OTV:MAPT) to initiate clinical studies in Alzheimer's disease in October 2025, expanding the pipeline.
• Submitted an Investigational New Drug (IND) application for DNL952 (ETV:GAA) to begin clinical studies in Pompe disease in October 2025, further diversifying the pipeline.
• Cash, cash equivalents, and marketable securities of $872.9 million as of September 30, 2025, are believed to be sufficient to fund projected operations through at least the next twelve months.

Negatives

• Net loss increased to $126.9 million for the three months ended September 30, 2025, from $107.2 million in the prior year period.
• Net loss increased to $384.0 million for the nine months ended September 30, 2025, from $308.0 million in the prior year period.
• The Phase 2/3 HEALEY ALS Platform Trial evaluating DNL343 did not meet its primary endpoint, and the active treatment extension was discontinued, representing a significant program setback.
• Sanofi terminated its license to the CNS Products program, including SAR443820/DNL788, in February 2025, eliminating future milestone or royalty payments from this program.
• Takeda terminated the ATV:TREM2 collaboration program on February 26, 2025, effective April 2025, resulting in no future milestones, cost, or profit sharing related to this agreement.
• The FDA extended its review timeline for the BLA seeking accelerated approval of tividenofusp alfa (DNL310) from January 5, 2026, to April 5, 2026, delaying a potential approval decision.
• Interest and other income, net, decreased by $5.5 million (34%) for the three months ended September 30, 2025, and by $15.5 million (31%) for the nine months ended September 30, 2025.
• The accumulated deficit reached $1.92 billion as of September 30, 2025, reflecting substantial historical losses.

Risks

• Limited operating history and no products approved for commercial sale make it difficult to evaluate current business and predict future success and viability.
• Significant net losses incurred since inception and anticipate continuing net losses for the foreseeable future.
• Drug development is a highly uncertain undertaking; may never generate product revenue or be profitable.
• Must prioritize development of certain product candidates due to significant resource requirements, potentially diverting resources from better opportunities.
• Heavy dependence on the successful development of TV technology and pipeline programs, which are in preclinical and clinical stages.
• May not be successful in efforts to create a pipeline of product candidates or to develop commercially successful products.
• Concentrated efforts on neurodegenerative and lysosomal storage diseases, fields that have seen limited success in drug development.
• May encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials on expected timelines, if at all.
• Difficulties enrolling and/or retaining patients in clinical trials could delay or otherwise adversely affect clinical development activities.
• Clinical trials may reveal significant adverse events, toxicities, or other side effects, or may fail to demonstrate substantial evidence of safety and efficacy, preventing, delaying, or limiting regulatory approval and commercialization.
• Significant competition in an environment of rapid technological and scientific change, which could adversely affect operating results.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties could hinder successful commercialization of approved product candidates.
• Product liability lawsuits could result in substantial liabilities and may require limiting commercialization of product candidates.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; inability to obtain regulatory approval means no product revenue.
• FDA, EMA, and applicable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Inability to obtain or maintain orphan drug designation benefits, including market exclusivity, which may reduce revenue.
• Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on business and results of operations.
• Business is subject to complex and evolving U.S. and foreign laws and regulations, information security policies, and contractual obligations relating to privacy, data protection, and data security.
• Dependence on collaborations with third parties for research, development, and commercialization of certain product candidates; if unsuccessful, market potential may not be realized.
• Reliance on third parties to conduct clinical trials and some aspects of research and preclinical testing; third parties may not perform satisfactorily.
• Reliance on third parties for the manufacture of the significant majority of materials for research programs, preclinical studies, and clinical trials may increase supply risk.
• Dependence on third-party suppliers for key raw materials; loss of these suppliers or their inability to supply adequate raw materials could harm business.
• Inability to obtain and maintain patent protection for product candidates or TV technology could allow competitors to develop and commercialize similar products.
• Owned or in-licensed patent applications may not issue as patents in any jurisdiction, impairing competitive effectiveness.
• Rights to develop and commercialize TV platform and product candidates are subject to license terms, which may not be exclusive or may be terminated.
• Inability to protect intellectual property and proprietary rights throughout the world.
• Patent protection could be reduced or eliminated for non-compliance with government patent agency requirements.
• Changes in U.S. patent law could diminish the value of patents in general, impairing ability to protect products.
• Issued patents covering TV platform, product candidates, and other technologies could be found invalid or unenforceable if challenged.
• Patent terms may be inadequate to protect competitive position on product candidates for an adequate amount of time.
• May be subject to claims challenging the inventorship of patents and other intellectual property.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• May not be successful in obtaining necessary rights to TV platform, product candidates, or other technologies through acquisitions, in-licenses, or otherwise.
• May be subject to claims that employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.
• Third-party claims of intellectual property infringement, misappropriation, or other violation against the company, its licensors, or collaborators may prevent or delay development and commercialization.
• Highly dependent on key personnel; inability to attract, motivate, and retain highly qualified personnel could hinder business strategy implementation.
• Need to grow the size and capabilities of the organization, which may lead to difficulties in managing growth.
• Acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, cause debt, or assume contingent liabilities.
• Internal computer systems, or those used by collaborators, CROs, or other contractors, may fail or suffer security breaches or incidents.
• Business disruptions, including as a result of geopolitical events and global pandemics, could seriously harm future revenue and financial condition and increase costs and expenses.
• Business is subject to economic, political, regulatory, and other risks associated with international operations.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Market price of common stock has been and may continue to be volatile, which could result in substantial losses for investors.
• If securities analysts publish negative evaluations of stock, or if they do not publish research or reports about business, the price of stock and trading volume could decline.
• Sales of substantial amounts of common stock in the public markets, or the perception that such sales might occur, could cause the market price of common stock to decline significantly.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Principal stockholders and management own a significant percentage of stock and will be able to exercise significant influence over matters subject to stockholder approval.
• Inability to maintain effective internal controls could adversely affect business, financial position, results of operations, and growth prospects.
• Do not expect to pay any dividends for the foreseeable future; investors may never obtain a return on their investment.
• Delaware law and provisions in charter documents might discourage, delay, or prevent a change in control of the company or changes in management, depressing the trading price of common stock.
• Amended and restated certificate of incorporation provides exclusive forums for substantially all disputes between the company and its stockholders, which could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances current clinical-stage programs, broadens and improves its TransportVehicle (TV) platform, acquires and develops additional product candidates, seeks regulatory approvals, protects intellectual property, and hires additional personnel. It anticipates needing substantial additional funding in the longer term to fund operations and meet future commitments. Preparations are underway for the commercial launch of tividenofusp alfa (DNL310), despite the BLA review extension. A global Phase 3 confirmatory study for DNL126 in MPS IIIA is being planned. Biogen expects a readout for the Phase 2b LUMA study for early-stage Parkinson's disease in 2026.

Management Comments

• We expect to continue to incur significant expenses and operating losses for the foreseeable future.
• Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates.
• We believe that our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund our projected operations through at least the twelve months following the filing date of this Quarterly Report on Form 10-Q.
• In the longer term, we anticipate that we will need substantial additional resources to fund our operations and meet future commitments.

Industry Context

Denali operates in the highly competitive and rapidly changing biopharmaceutical industry, specifically focusing on neurodegenerative and lysosomal storage diseases, fields historically characterized by limited drug development success. The company's strategy leverages its TransportVehicle (TV) platforms to enhance drug delivery across the blood-brain barrier (BBB), a novel approach in these challenging disease areas. The termination of collaborations (Sanofi CNS, Takeda ATV:TREM2) highlights the inherent risks and high attrition rates in drug development, even for partnered programs. The FDA's Breakthrough Therapy Designation for DNL310 and alignment on a surrogate endpoint for DNL126 suggest regulatory recognition of the unmet need and potential of novel approaches in rare diseases, potentially setting new precedents for accelerated approvals in these fields. The opening of an internal biomanufacturing facility reflects a trend towards greater control over supply chains and operational efficiency in the biologics sector.

Comparison to Industry Standards

• The failure of the DNL343 ALS trial is consistent with the high failure rate in neurodegenerative disease drug development, where many companies, including major pharmaceutical players, have faced setbacks.
• The FDA's Breakthrough Therapy Designation for DNL310 for MPS II and the acceptance of its BLA for priority review indicate DNL310 is performing well relative to the standard of care and other investigational therapies for Hunter syndrome, a rare lysosomal storage disease with significant unmet needs.
• The alignment with the FDA on CSF heparan sulfate as a reasonably likely surrogate endpoint for DNL126 in MPS IIIA is a significant positive, as establishing such endpoints can accelerate development and approval pathways, a strategy often pursued by companies developing therapies for rare diseases where traditional clinical endpoints are difficult to achieve quickly.
• The termination of the Sanofi CNS Products program and Takeda ATV:TREM2 collaboration reflects the common practice in the pharmaceutical industry where partnerships are re-evaluated and programs discontinued based on preclinical or early clinical data, strategic shifts, or mutual agreement, as seen with many other companies in the competitive neurodegenerative space.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any litigation or legal proceedings that are likely to have a material adverse effect on the business.
• Litigation, regardless of outcome, can have an adverse impact due to defense and settlement costs, diversion of management attention, and resources.

Related Party Transactions

• The company has collaboration agreements with Takeda, Sanofi, and Biogen, which involve cost-sharing payments, reimbursements, and potential milestone/royalty payments.
• A private placement in February 2024 involved certain existing accredited investors, with one investor granted director nomination and additional registration rights.
• Baker Brothers Life Sciences L.P. and 667, L.P. ('Baker Brothers') designated a director to the Board pursuant to a nominating agreement.

Stakeholder Impact

• Shareholders: Increased net losses and the DNL310 BLA review extension could negatively impact short-term share price. Program terminations (DNL343, Sanofi CNS, Takeda ATV:TREM2) represent setbacks. However, positive clinical developments (DNL310 Breakthrough Therapy, DNL126 surrogate endpoint, new IND/CTA filings) and a strong cash position provide long-term potential. Dilution risk from future capital raises.
• Employees: Management changes (CMO departure, acting CMO appointment) could create uncertainty. Expansion of manufacturing capabilities (Salt Lake City facility) may create new opportunities.
• Customers/Patients: Potential for DNL310 approval for MPS II offers a new treatment option. Progress in DNL126 for MPS IIIA and new programs for AD and Pompe disease offer future hope for patients with neurodegenerative and lysosomal storage diseases. DNL343 ALS trial failure is a disappointment for ALS patients.
• Collaboration Partners (Biogen, Takeda, Sanofi): Terminations of certain programs reflect the high-risk nature of drug development and impact future collaboration revenue for Denali. Ongoing collaborations (Biogen LRRK2, Takeda PTV:PGRN, Sanofi RIPK1) continue.
• Creditors: Strong cash and marketable securities position ($872.9 million) provides liquidity and reduces immediate credit risk, but ongoing losses and future funding needs are noted.

Next Steps

• Prepare for commercial launch of tividenofusp alfa (DNL310).
• Await FDA decision on DNL310 BLA by April 5, 2026.
• Plan a global Phase 3 confirmatory study for DNL126 in MPS IIIA.
• Initiate clinical studies for DNL628 (OTV:MAPT) in Alzheimer's disease.
• Begin clinical studies for DNL952 (ETV:GAA) in Pompe disease.
• Await readout for Biogen's Phase 2b LUMA study for Parkinson's disease in 2026.
• Evaluate the impact of new FASB accounting standards (ASU 2023-09 and ASU 2024-03) on financial statements and disclosures.

Key Dates

Recommendation

The company presents a mixed bag of results. While the increased net losses and the failure of the DNL343 ALS trial are significant negatives, the progress with DNL310 (Breakthrough Therapy, priority BLA review, despite extension) and DNL126 (surrogate endpoint alignment, Phase 3 planning) in rare diseases are strong positives that could drive future value. The termination of two collaboration programs (Sanofi CNS, Takeda ATV:TREM2) is a setback but also allows for resource reallocation. The company maintains a solid cash position for the next 12 months, but the long-term need for additional capital and the inherent risks of clinical-stage biopharmaceutical development warrant caution. The stock is likely to experience volatility based on clinical trial readouts and regulatory decisions. A 'hold' recommendation reflects the balance between the significant potential of its lead programs and the substantial risks and ongoing losses inherent in its business model. Investors should monitor DNL310's BLA decision and DNL126's Phase 3 progress closely.

Keywords

Neurodegenerative Diseases, Lysosomal Storage Diseases, Blood-Brain Barrier, TransportVehicle Platform, DNL310, Tividenofusp Alfa, MPS II, Hunter Syndrome, DNL126, MPS IIIA, Sanfilippo Syndrome, DNL628, Alzheimer's Disease, DNL952, Pompe Disease, Parkinson's Disease, BIIB122, DNL151, LRRK2 Inhibitor, Biologics License Application, Breakthrough Therapy Designation, Clinical Trials, Biopharmaceutical, Drug Development, SEC Filing, 10-Q